



RECEIVED

Express Mail No.: EL 477 037 351 US

JUN 04 2002

TECH CENTER 1600/2900

Sheet 1 of 2

<b>SUPPLEMENTAL LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)				ATTY. DOCKET NO. 8449-123-999		APPLICATION NO. 09/625,137	
				APPLICANT Srivastava, Pramod K.			
				FILING DATE July 25, 2000		GROUP 1642	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CY	CU	5,968,526	10/19/99				6/07/95
CY	CV	US 2002/0001841 A1	1/03/02				6/25/99
CY	CW	6,156,311	12/05/00				7/26/96
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
CY	CC	WO 00/03003	1/20/00	PCT			
	CY	WO 98/42752	10/01/98	PCT			
	CZ	WO 00/34494	6/15/00	PCT			
	DA	WO 98/46739	7/23/97	PCT			X
	DB	WO 97/04794	2/13/97	PCT			
CY	DC	WO 00/46246	8/10/00	PCT			
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
CY	DD	Agostoni et al., 1994, "Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator." Circulation. 90(6):2666-70.					
	DE	Bednar et al., 1997, "Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke." J. Neurosurg. 86(1):139-42.					
	DF	Collen et al., 1989, "Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent." Drugs. 38(3):346-88.					
	DG	Hanover et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.					
	DH	Herz et al., 1990, "Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver", J. of Biol. Chem. 265(34): 21355-21362.					
	DI	Herz et al., 1991, "39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha-2-macroglobulin receptor." J.Biol.Chem. 266(31):21232-21238.					
	DJ	Hey et al., 1988, "Cloning of a novel member of the low-density lipoprotein receptor family", Gene 216: 103-111.					
	DK	Horn et al., 1995, "Analysis of the binding of Pro-urokinase and urokinase-plasminogen activator inhibitor-I complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library", J. of Biol. Chem. 270 (20): 11770-11775.					
	DL	Huang et al., 1996, "The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product", Proc. Natl. Acad. Sci. USA. 93: 9730-9735.					
CY	DM	Hughes et al., 1981, "Characterization of plasma membrane proteins identified by monoclonal antibodies", J. of Biol./ Chem. 256(2): 664-671.					



	DM	Isaacs et al., 1988, "Use of anti-idiotypic antibodies to establish that monoclonal antibody 7H11D6 binds to the alpha2-macroglobulin receptor recognition site", J. Biol. Chem. 263(14): 6709-6714.
	DO	Katsutani et al., 1992, "Immunogenic properties of structurally modified human tissue plasminogen activators in chimpanzees and mice." Fundam Appl Toxicol. 19(4):555-62.
	DP	Kim et al., 1998, "A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognized apolipoprotein E", J. Biochem. 124: 1072-1076.
	DQ	Kimber et al., 2002, "Lactoferrin: influences on langerhans cells, epidermal cytokines, and cutaneous inflammation." Biochem Cell Biol. 2002;80(1):103-7.
	DR	Moestrup et al., 1990, "Immunocytochemical identification of the human alpha 2-macroglobulin receptor in monocytes and fibroblasts: monoclonal antibodies define the receptor as a monocyte differentiation antigen", Exper. Cell Res. 190: 195-203.
	DS	Moestrup et al., 1991, "Analysis of Ligand Recognition by the purified alpha-2M- macroglobulin receptor (low density lipoprotein receptor-related protein). J. Biol. Chem. 266(21):14011-14017.
	DT	Opekun et al., 1999, "Novel therapies for Helicobacter pylori infection." Aliment Pharmacol Ther. 13(1):35-42.
	DU	Reed et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80.
	DV	Warshawaky et al., 1993, "Identification of domains in the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054.
	DW	Yamauchi et al., 2000, "Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study." Mycoses. 43(5):197-202.
	DX	Zimecki et al., 1999, "Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells." Arch Immunol Ther Exp (Warsz). 47(2):113-8.
SY	DY	Zimecki et al., 1998, "Immunoregulatory effects of a nutritional preparation containing bovine lactoferrin taken orally by healthy individuals." Arch Immunol Ther Exp (Warsz). 46(4):231-40.
EXAMINER <u>Christopher HY</u>		DATE CONSIDERED <u>12/26/02</u>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

JUN 04 2002

TECH CENTER 1600/2900